Loading…
Kamada Ltd. is projected to rise to $7.99 by 2027, a +12% move from its current price of $7.14. KMDA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $7.04 | $7.14 | $7.24 | +0.02% |
| Aug 4 | $7.01 | $7.14 | $7.28 | +0.04% |
| Aug 5 | $6.98 | $7.14 | $7.32 | +0.07% |
| Aug 6 | $6.95 | $7.15 | $7.35 | +0.09% |
| Aug 7 | $6.93 | $7.15 | $7.37 | +0.11% |
| Aug 8 | $6.91 | $7.15 | $7.39 | +0.13% |
| Aug 9 | $6.89 | $7.15 | $7.42 | +0.15% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $6.89 | $7.15 | $7.42 | +0.15% |
| Week 2 | $6.80 | $7.16 | $7.54 | +0.30% |
| Week 3 | $6.73 | $7.17 | $7.64 | +0.46% |
| Week 4 | $6.68 | $7.18 | $7.73 | +0.61% |
| Week 5 | $6.63 | $7.19 | $7.81 | +0.76% |
| Week 6 | $6.59 | $7.21 | $7.88 | +0.92% |
| Week 7 | $6.55 | $7.22 | $7.95 | +1.07% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite.
The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
Kamada Ltd. (KMDA) is a healthcare company focused on plasma-derived protein therapeutics. It operates within the healthcare sector and holds a market capitalization of $421.75M with a rank of 3201.
The current price is $7.31, reflecting the stock’s place in the market today. The near-term trading picture combines a current price near the SMA lines with a defined support at $7.13 and resistance at $7.98.
A major floor 7.8% below — a decisive break under it would weaken the trend.
The nearest floor, 3.2% below — buyers have tended to step in here.
The nearest ceiling, 5.3% above — a clean break opens room to run.
A major ceiling 19.7% above — clearing it would confirm fresh momentum.
Key KMDA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of KMDA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $7.06 | Buy | $7.08 | Buy |
| MA 10 | $7.07 | Buy | $7.08 | Buy |
| MA 20 | $7.13 | Buy | $7.13 | Buy |
| MA 50 | $7.33 | Sell | $7.36 | Sell |
| MA 100 | $7.83 | Sell | $7.59 | Sell |
| MA 200 | $7.71 | Sell | $7.60 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.25 | Neutral |
| Stoch RSI (14) | 92.02 | Sell |
| CCI (20) | 6.23 | Neutral |
| Williams %R (14) | -37.84 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | -0.14 | Sell |
| Bollinger %B (20,2) | 0.52 | Neutral |
| Stochastic %K (14) | 62.16 | Neutral |
| TRIX (15) | -0.20 | Sell |
| Awesome (5,34) | -0.15 | Sell |
| Ultimate (7,14,28) | 57.49 | Neutral |
| Momentum (10) | 0.09 | Buy |
| Aroon Osc (25) | -40.00 | Sell |
| Hull MA (9) | 7.08 | Buy |
| ADX (14) | 15.24 | Neutral |
| ATR (14) | 0.09 | Info |
The 30-day technical picture is neutral overall, with RSI(14) at 40. The stock’s 50-day simple moving average stands at $7.71 and the 200-day SMA at $7.69, indicating a fairly balanced trend near the current level. A key near-term support sits at $7.13 and resistance at $7.98, framing a small trading band.
The 30-day price range spans from $6.68 to $8.00, underscoring modest volatility in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $6.91 | $7.14 | $9.09 | 0% | Neutral | |
| $6.55 | $7.99 | $10.18 | +12% | Neutral | |
| $6.75 | $8.39 | $10.98 | +18% | Neutral | |
| $8.19 | $10.33 | $13.82 | +45% | Bullish | |
| $9.18 | $11.75 | $16.00 | +65% | Bullish | |
| $9.89 | $12.80 | $17.71 | +79% | Bullish | |
| $10.47 | $13.72 | $19.25 | +92% | Bullish | |
| $10.28 | $13.61 | $19.34 | +91% | Bullish | |
| $10.98 | $14.67 | $21.11 | +106% | Bullish | |
| $12.45 | $16.80 | $24.44 | +135% | Bullish | |
| $16.55 | $23.29 | $35.51 | +226% | Bullish | |
| $33.97 | $51.29 | $83.83 | +618% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $6.91 | $7.14 | $8.56 | +0.00% |
| September 2026 | $6.28 | $7.36 | $8.82 | +3.08% |
| October 2026 | $6.18 | $7.28 | $8.80 | -1.04% |
| November 2026 | $6.11 | $7.23 | $8.78 | -0.75% |
| December 2026 | $6.27 | $7.44 | $9.09 | +2.97% |
Click any year to see its month-by-month KMDA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The KMDA price prediction for 2026 points to an average of $7.14 (low $6.91, high $9.09) — a potential gain of 0% on today's $7.14. Price action looks broadly range-bound.
In 2027, KMDA is projected to trade between $6.55 and $10.18, averaging $7.99 — a potential gain of +12% from today's $7.14. That is up +12% on the projected 2026 average. A consolidation phase looks the most probable path here.
Kamada Ltd.'s 2028 outlook centres on $8.39, within a $6.75 to $10.98 range. That is up +5% on the projected 2027 average. That marks a +18% change versus current levels. Price action looks broadly range-bound.
By 2029, KMDA could reach as high as $13.82, with a base case around $10.33 and support toward $8.19 — roughly +45% from $7.14. Buyers look set to stay in control over this stretch.
Expect KMDA to range from $9.18 to $16.00 through 2030. The $11.75 average target implies a +65% move from current prices. That is up +14% on the projected 2029 average. Momentum favours further upside here.
The KMDA price prediction for 2031 points to an average of $12.80 (low $9.89, high $17.71) — a potential gain of +79% on today's $7.14. Buyers look set to stay in control over this stretch.
In 2032, KMDA is projected to trade between $10.47 and $19.25, averaging $13.72 — a potential gain of +92% from today's $7.14. That is up +7% on the projected 2031 average. Momentum favours further upside here.
Kamada Ltd.'s 2033 outlook centres on $13.61, within a $10.28 to $19.34 range. That is -1% versus the projected 2032 average. That marks a +91% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, KMDA could reach as high as $21.11, with a base case around $14.67 and support toward $10.98 — roughly +106% from $7.14. Momentum favours further upside here.
Expect KMDA to range from $12.45 to $24.44 through 2035. The $16.80 average target implies a +135% move from current prices. That is up +15% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The KMDA price prediction for 2040 points to an average of $23.29 (low $16.55, high $35.51) — a potential gain of +226% on today's $7.14. Momentum favours further upside here.
In 2050, KMDA is projected to trade between $33.97 and $83.83, averaging $51.29 — a potential gain of +618% from today's $7.14. That is up +120% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in KMDA today (≈ 140.056022 KMDA) could be worth
$7,182.95
+$6,182.95 (+618%) by 2050 · US Dollar
Based on the average projected KMDA price of $51.29 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in KMDAwould be worth at today's price.
$1,000 invested in KMDA on Jul 31, 2025 (≈ 135.318 KMDA) would be worth
$966.17
-$33.83 (-3.4%) today · 0.97× · US Dollar
Based on a KMDA entry price of $7.39 vs. today's $7.14.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $7.06 | $1,011.33 | +1.1% |
| 1 month ago | $7.52 | $949.47 | -5.1% |
| 3 months ago | $8.21 | $869.67 | -13.0% |
| 6 months ago | $8.24 | $866.5 | -13.3% |
| 1 year ago | $7.39 | $966.17 | -3.4% |
| All time (5.0y) ago | $5.78 | $1,235.29 | +23.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our KMDA forecast.
Our base-case forecast reaches $14.00 around 2034.
Implied market cap at $14.00: $807.72M
The year-by-year forecast shows a path from a 2026 average price of $7.31 toward progressively higher levels, ending with a 2050 average of $49.13 and a 572.1% ROI. The 2026 forecast carries an average of $7.31 with a 0% ROI and a neutral sentiment, while 2029–2032 turn bullish as averages rise to $10.47, $11.64 and $12.76 respectively, with ROIs of 43.3%, 59.2% and 74.6%. By 2034 the average reaches $14.61, and 2035 shows $16.65 with a 127.8% ROI.
The forecast then accelerates: 2040 average $22.69 with a 210.4% ROI, and by 2050 the average is $49.13 with a 572.1% ROI, all under bullish sentiment. These figures imply meaningful upside over the long term, though the outlook remains subject to uncertainty and is not guaranteed.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $11.64 with a range from $9.09 to $15.86 and an estimated ROI of 59.2%. The sentiment is BULLISH.
The forecast increases from a neutral stance in 2026 (avg $7.31) to bullish in later years, with 2029–2032 showing higher averages (e.g., 2029 avg $10.47; 2030 avg $11.64) and ROIs up to 59.2%. By 2040 the forecast shows an average of $22.69 and a 210.4% ROI, with a 2050 average of $49.13 and a 572.1% ROI, indicating substantial upside potential but not a guarantee.
Yes. The forecast for 2030 lists a maximum price of $15.86, and 2031 lists a maximum of $17.68, indicating that a price around or above $15 is within the projected range.
For 2040, the average price is forecast at $22.69, with a minimum of $16.11 and a maximum of $34.62, and a 210.4% ROI. The sentiment is BULLISH.
The numbers represent estimates and are not guaranteed. The current price is $7.31, and the forecast shows substantial upside in some years, but the outcomes are uncertain and can be affected by factors not captured in the numbers; historical volatility is indicated at about 30% annualized.
Kamada Ltd. Community Discussion
0Share your Kamada Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.